MARKET

CLSD

CLSD

Clearside
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.580
-0.020
-1.25%
Closed 16:00 04/03 EDT
OPEN
1.610
PREV CLOSE
1.600
HIGH
1.640
LOW
1.530
VOLUME
128.25K
TURNOVER
--
52 WEEK HIGH
4.130
52 WEEK LOW
0.5600
MARKET CAP
70.89M
P/E (TTM)
-1.8663
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLSD stock price target is 4.500 with a high estimate of 6.00 and a low estimate of 3.000.

EPS

CLSD News

More
  • Edited Transcript of CLSD earnings conference call or presentation 11-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 5d ago
  • The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty
  • Benzinga · 6d ago
  • Clearside Biomedical (CLSD) Investor Presentation - Slideshow
  • Seeking Alpha - Article · 03/17 11:33
  • Week In Review: Nanjing Legend Files To Stage IPO In The U.S.
  • Seeking Alpha - Article · 03/15 11:46

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About CLSD

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting three components of the eye: the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision; the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment, and the sclera, which is the outer protective layer of the eye. The Company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide formulated for administration via suprachoroidal injection.
More

Webull offers kinds of Clearside Biomedical Inc stock information, including NASDAQ:CLSD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSD stock news, and many more online research tools to help you make informed decisions.